A Study Of Sclerostin Inhibition On T Cell Aging

Overview

About this study

The purpose of this study is to analyze T cells collected from patients before and after treatment with romosozumab to determine whether Wnt signaling is activated and whether there is an effect on T cell regenerative potential.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Postmenopausal women (age > 50, no menses for at least 1 year) weighing at least 110 pounds who are initiating treatment with romosozumab for the indication of postmenopausal osteoporosis.

Exclusion Criteria: 

  • Presence of (documented clinical diagnosis of any of the following:

    • Diabetes mellitus requiring insulin.

    • Significant liver or renal disease (liver disease based on abnormal labs; chronic kidney disease stage 4 or 5, or on dialysis)

    • Malignancy (current diagnosis of any cancer including melanoma and myeloma; for subjects with a previous diagnosis of cancer and no evidence of active or recurrent disease, the PI will determine eligibility on a case-by-case basis)

    • Chemotherapy within the past 3 years.

    • Radiation (the PI will determine eligibility on a case-by-case basis)

    • Malabsorption (current clinical diagnosis or currently receiving treatment)

    • Hypoparathyroidism (current clinical diagnosis or currently receiving treatment)

    • Hyperparathyroidism (current clinical diagnosis or currently receiving treatment)

    • Acromegaly

    • Cushing syndrome

    • Hypopituitarism

    • Severe chronic obstructive pulmonary disease

    • Pheochromocytoma (current clinical diagnosis or currently receiving treatment)

    • Active bronchospastic disease with treatment (asthma, bronchitis)

    • Gastric bypass

    • Parkinson disease

    • Rheumatoid arthritis

    • Psoriatic arthritis

    • Connective tissue disease

    • Active atrial fibrillation (controlled or uncontrolled)

  • Undergoing treatment with any medications that may have immunomodulating properties, including the following:

    • Glucocorticoids (oral for > 3 months within the past 12 months or year-round use of inhaled corticosteroids)

    • Relevant rheumatologic medications (methotrexate, mycophenolate, JAK/STAT inhibitors)

    • Denosumab (within the past 12 months)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/03/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jorg Goronzy, M.D., Ph.D.

Open for enrollment

Contact information:

Amanda Tweed

5072556663

tweed.amanda@mayo.edu

More information

Publications

Publications are currently not available